{"slug":"pinealon","seoKey":"pinealon","displayName":"Pinealon","codes":["T-33"],"synonyms":["Glu-Asp-Arg","EDR","EDR peptide","H-Glu-Asp-Arg-OH","L-glutamyl-L-aspartyl-L-arginine","glutamyl-aspartyl-arginine (the NLM MeSH supplementary concept heading)","T-33 peptide","Pinealon / Пинеалон (Russian trade name)"],"legalClass":"research_chemical","identifiers":{"cas":"175175-23-2","pubchemCid":10273502,"inchikey":"QPRZKNOOOBWXSU-CIUDSAMLSA-N","formula":"C15H26N6O8","molecularWeight":418.4,"sequence":"EDR","wikidataQid":"Q106026341"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not registered as a substance. Four federal queries returned no match on 2026-09-10: no drug label, no entry in the labelling database, no record in the substance registration system, which is why there is no UNII, and no marketing as a dietary supplement. Control queries with an approved active ingredient returned hits in each interface. The substance has also never been nominated for the compounding bulks list, whose full text was checked; the same list carries other grey-market peptides in category 1, so this is an absence and not an oversight. US distribution runs through the research-chemical channel under a research-use-only label, that is, explicitly not for human use.","source":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22Pinealon%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no pharmacopoeial monograph. The register itself could not be queried on 2026-09-10: the result page and a control page for an approved active ingredient both returned a JavaScript shell of almost identical size without server-rendered hits. This is therefore a negative finding drawn from the absence of any entry in every other authority database checked and from the absence of any registered clinical study.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=pinealon"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists, so an injectable preparation is not a marketable medicinal product and may not be imported or dispensed. The oral Russian food-supplement form does not become marketable by being imported either: its peptide complexes are not documented as a food or food ingredient consumed to a significant degree before 15 May 1997, so the novel food regulation applies. The substance is also not named in the schedule to the Anti-Doping Act, whose section on peptide hormones, growth factors, related substances and mimetics lists what it covers by name and exhaustively; a tripeptide without hormone or releasing-factor activity falls under none of those items. The full text was checked on 2026-09-10. Sporting rules are unaffected by that.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register returned only the JavaScript shell of its search page on 2026-09-10 and a control query with an approved active ingredient produced a byte-for-byte identical response size, so the negative finding could not be verified positively. It rests on the absence of any entry elsewhere and on the absence of any clinical development.","source":"https://products.mhra.gov.uk/search/?search=pinealon"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard; the full text of the June 2026 instrument was searched on 2026-09-10 for the trade name, the sequence, the code and the chemical name without a hit, while a control term was found twice, so the search worked. There is no generic peptide position in that instrument, and short peptides are listed by name where they are scheduled, so this is a real absence. Absence of a listing is not a clearance: unregistered therapeutic goods remain subject to registration requirements, and the registry itself was not programmatically queryable.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database; the query returned an empty result on 2026-09-10, while a control query for an authorised product returned six records with its identification number, so the interface was working.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=pinealon"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. No direct register query was possible on 2026-09-10, so this is a negative finding drawn from the absence of an authorisation in every market that could be checked and from the absence of any registered clinical study anywhere.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"preclinical","strongestEvidence":"observational","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/10273502","https://www.wikidata.org/wiki/Q106026341"],"lastVerified":"2026-09-10","version":"1.0","published":true,"locale":"en","title":"Pinealon: what the studies show, status and safety","summary":"Pinealon is a synthetic chain of three amino acids from a St Petersburg institute. The name points at the pineal gland, but the peptide comes from a brain cortex extract, and in pineal tissue culture it did nothing at all. No trial in people has ever been registered. The best animal study missed its main measurement, was beaten by a rival peptide and had to be formally corrected in 2025.","updated":"2026-09-10","url":"https://mypep.app/peptides/pinealon"}